Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat Autònoma de Barcelona > Articles escrits per personal UAB o publicats per la universitat > View document

Title:	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Author:	Trilla-Fuertes, Lucía; Gámez-Pozo, Angelo; Maurel, Joan; García-Carbonero, Rocío; Capdevila Castillón, Jaume; G-Pastrián, Laura; Mendiola, Marta; Peña, Cristina; López-Vacas, Rocío; Cuatrecasas, Miriam; García-Alfonso, Pilar; Ramos-Ruiz, Ricardo; Llorens, Carlos; Ghanem, Ismael; Conill, Carles; Heredia Soto, Victoria; Campos-Barros, Ángel; Fresno Vara, Juan Ángel; Feliu, Jaime; Universitat Autònoma de Barcelona
Abstract:	Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). However, in T3/T4 tumors, the 3-year relapse free survival rate is only 50%. The VITAL trial aimed to assess the efficacy and safety of panitumumab in combination with this standard treatment. In this study, 27 paraffin-embedded samples from the VITAL trial and 18 samples from patients from daily clinical practice were analyzed by whole-exome sequencing and the influence of the presence of genetic variants in the response to panitumumab was studied. Having a moderate- or high-impact genetic variant in PIK3CA seemed to be related to the response to panitumumab. Furthermore, copy number variants in FGFR3, GRB2 and JAK1 were also related to the response to panitumumab. These genetic alterations have also been studied in the cohort of patients from daily clinical practice (not treated with panitumumab) and they did not have a predictive value. Therefore, in this study, a collection of genetic alterations related to the response with panitumumab was described. These results could be useful for patient stratification in new anti-EGFR clinical trials
Subject(s):	-Cancer -Medical genetics -Predictive markers
Rights:	open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/
Document type:	Article
Published by:
Share:
Uri:	https://ddd.uab.cat/record/255396

Show full item record

Related documents

Other documents of the same author

Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma

Trilla-Fuertes, Lucía; Ghanem, Ismael; Maurel, Joan; G-Pastrián, Laura; Mendiola, Marta; Peña, Cristina; López-Vacas, Rocío; Prado-Vázquez, Guillermo; López-Camacho, Elena; Zapater-Moros, Andrea; Heredia Soto, Victoria; Cuatrecasas, Miriam; García-Alfonso, Pilar; Capdevila Castillón, Jaume; Conill, Carles; García-Carbonero, Rocío; Heath, Karen E.; Ramos-Ruiz, Ricardo; Llorens, Carlos; Campos-Barros, Ángel; Gámez-Pozo, Angelo; Feliu, Jaime; Vara, Juan Ángel Fresno

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Codony-Servat, Jordi; Cuatrecasas, Miriam; Asensio, Elena; Montironi, Carla; Martínez Cardús, Anna; Marín Aguilera, Mercedes; Horndler, Carlos; Martínez Balibrea, Eva; Rubini, Michele; Jares, Pedro; Reig, Oscar; Victoria, Iván; Gaba, Lydia; Martín Richard, Marta; Alonso, Vicente; Escudero, Pilar; Fernández-Martos, Carlos; Feliu, Jaime; Méndez, Jose Carlos; Méndez, Miguel; Gallego, Javier; Salud, Antonieta; Rojo, Federico; Castells, Antoni; Prat, Aleix; Rosell, Rafael; García-Albéniz, Xabier; Camps, Jordi; Maurel, Joan; Universitat Autònoma de Barcelona

Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

García-Alfonso, Pilar; García-Carbonero, Rocío; García-Foncillas, Jesús; Pérez-Segura, Pedro; Salazar, R.; Vera, Ruth; Ramón y Cajal, S.; Hernández-Losa, J.; Landolfi, Stefania; Musulén, Eva; Cuatrecasas, Miriam; Navarro, S.; Universitat Autònoma de Barcelona

Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS Wild-Type metastatic colorectal cancer patients

Alonso, Vicente; Escudero, Pilar; Fernández-Martos, Carlos; Salud Salvia, Maria Antonieta; Méndez, Miguel; Gallego, Javier; Rodriguez, Jose-R.; Martín-Richard, Marta; Fernández-Plana, Julen; Manzano, Hermini; Méndez, José-Carlos; Zanui, Monserrat; Falcó, Esther; Gil-Raga, Mireia; Rojo, Federico; Cuatrecasas, Miriam; Feliu, Jaime; García-Albéniz, Xabier; Maurel, Joan

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set

Grothey, Axel; Yoshino, Takayuki; Bodoky, Gyorgy; Ciuleanu, Tudor Eliade; García-Carbonero, Rocío; García-Alfonso, Pilar; Van Cutsem, Eric; Muro, Kei; Mytelka, Daniel S.; Li, Li; Lipkovich, Olga; Hsu, Yanzhi; Sashegyi, Andreas; Ferry, David; Nasroulah, Federico; Tabernero, Josep; Universitat Autònoma de Barcelona

Accesibility | Legal note | Cookies Policy

Coordination

Supporters